Compare Deere & Company (DE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Zimmer Biomet Holdings Inc — how do they compare? Deere & Company trades at $618.3 (market cap $164.47B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Deere & Company is far larger — about 8.8× Zimmer Biomet Holdings Inc's market cap, and Deere & Company pays the higher dividend (1.06%). Which is the better fit depends on your goals.
| DE | ZBH | |
|---|---|---|
Market Cap | $164.47B | $18.65B |
Sector | Industrials | Health |
52-Week High | $662.49 | $107.71 |
52-Week Low | $439.11 | $79.58 |
Enterprise Value | $219.29B | $25.72B |
Dividend Yield | 1.06% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $620.83, up 0.97% for the day, with a bullish technical outlook supported by moving averages and recent earnings beats. Revenue declined to $44.67B in 2025, but net income margins remain healthy at 10.33%. The stock is near its pivot point of $620, with support at $613 and resistance at $628. Analyst consensus is a Moderate Buy with a $676.08 price target, reflecting optimism despite cyclical headwinds in agricultural equipment demand.
The outlook is cautiously positive, driven by consistent earnings outperformance and strong institutional holdings, but investors face risks from revenue volatility and high debt levels. The stock offers value if agricultural recovery materializes, but macroeconomic sensitivity warrants monitoring.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
